213 related articles for article (PubMed ID: 19835664)
1. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.
Katz D; Lazar A; Lev D
Expert Rev Mol Med; 2009 Oct; 11():e30. PubMed ID: 19835664
[TBL] [Abstract][Full Text] [Related]
2. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
4. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
8. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
Dang I; DeVries GH
J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
[TBL] [Abstract][Full Text] [Related]
9. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
10. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
11. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
13. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
14. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
15. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
16. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
17. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.
Ki DH; He S; Rodig S; Look AT
Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka BN; Sadek A; McKay RM; Le LQ
Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
[TBL] [Abstract][Full Text] [Related]
20. p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs.
Grit JL; McGee LE; Tovar EA; Essenburg CJ; Wolfrum E; Beddows I; Williams K; Sheridan RTC; Schipper JL; Adams M; Arumugam M; Vander Woude T; Gurunathan S; Field JM; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Oncogene; 2024 May; 43(19):1411-1430. PubMed ID: 38480916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
